196 related articles for article (PubMed ID: 38939189)
1. SARS-CoV-2: pathogenesis, therapeutics, variants, and vaccines.
Li X; Mi Z; Liu Z; Rong P
Front Microbiol; 2024; 15():1334152. PubMed ID: 38939189
[TBL] [Abstract][Full Text] [Related]
2. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection.
Liang Y; Wang ML; Chien CS; Yarmishyn AA; Yang YP; Lai WY; Luo YH; Lin YT; Chen YJ; Chang PC; Chiou SH
Front Immunol; 2020; 11():1022. PubMed ID: 32574260
[TBL] [Abstract][Full Text] [Related]
3. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
4. Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19.
Kumar R; Rathi H; Haq A; Wimalawansa SJ; Sharma A
Virus Res; 2021 Jan; 292():198235. PubMed ID: 33232783
[TBL] [Abstract][Full Text] [Related]
5. COVID-19: imbalanced cell-mediated immune response drives to immunopathology.
Wang J; Li Q; Qiu Y; Lu H
Emerg Microbes Infect; 2022 Dec; 11(1):2393-2404. PubMed ID: 36069182
[TBL] [Abstract][Full Text] [Related]
6. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
[TBL] [Abstract][Full Text] [Related]
7. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
Abdurrahman L; Fang X; Zhang Y
Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
[TBL] [Abstract][Full Text] [Related]
8. Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination, Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory Responses.
Rabaan AA; Al-Ahmed SH; Garout MA; Al-Qaaneh AM; Sule AA; Tirupathi R; Mutair AA; Alhumaid S; Hasan A; Dhawan M; Tiwari R; Sharun K; Mohapatra RK; Mitra S; Emran TB; Bilal M; Singh R; Alyami SA; Moni MA; Dhama K
Pathogens; 2021 May; 10(5):. PubMed ID: 34066983
[TBL] [Abstract][Full Text] [Related]
9. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
10. Next-generation treatments: Immunotherapy and advanced therapies for COVID-19.
Arevalo-Romero JA; Chingaté-López SM; Camacho BA; Alméciga-Díaz CJ; Ramirez-Segura CA
Heliyon; 2024 Mar; 10(5):e26423. PubMed ID: 38434363
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Immuno-Pathogenesis and Potential for Diverse Vaccines and Therapies: Opportunities and Challenges.
McGill AR; Kahlil R; Dutta R; Green R; Howell M; Mohapatra S; Mohapatra SS
Infect Dis Rep; 2021 Feb; 13(1):102-125. PubMed ID: 33557330
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
Gong W; Parkkila S; Wu X; Aspatwar A
Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
[TBL] [Abstract][Full Text] [Related]
14. Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants.
Noor R
Viruses; 2022 Nov; 14(11):. PubMed ID: 36423150
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies.
Salimi-Jeda A; Abbassi S; Mousavizadeh A; Esghaie M; Bokharaei-Salim F; Jeddi F; Shafaati M; Abdoli A
Int Immunopharmacol; 2021 Dec; 101(Pt A):108232. PubMed ID: 34673335
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory agents as potential therapeutic or preventive strategies for COVID-19.
Gaziano R; Pistoia ES; Campione E; Fontana C; Marino D; Favaro M; Pica F; Di Francesco P
Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4174-4184. PubMed ID: 34156699
[TBL] [Abstract][Full Text] [Related]
17. The COVID-19 inflammation and high mortality mechanism trigger.
Stróż S; Kosiorek P; Stasiak-Barmuta A
Immunogenetics; 2024 Feb; 76(1):15-25. PubMed ID: 38063879
[TBL] [Abstract][Full Text] [Related]
18. Research progress in spike mutations of SARS-CoV-2 variants and vaccine development.
He X; He C; Hong W; Yang J; Wei X
Med Res Rev; 2023 Jul; 43(4):932-971. PubMed ID: 36929527
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
